News | January 08, 2026
Arrowhead Pharmaceuticals gets green light for first-of-its-kind FCS therapy
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The approval is supported by data from three pivotal clinical trials
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
Applications include detailed scientific rationale and supporting clinical evidence
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
Subscribe To Our Newsletter & Stay Updated
